Skip to content

Clinical trials

Phase 1/2 Hematologic Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hematologic Neoplasms Phase: Phase 1/2 Clear all

143 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20024
20031
20042
20052
20067
20075
20082
20097
20106
20114
20123
20136
20147
20154
20165
201710
20183
201910
20205
202114
20227
20238
20246
20255
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed53
Recruiting26
Terminated20
Unknown status20
Active, not recruiting11
Withdrawn8
Not yet recruiting5

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center8
National Cancer Institute (NCI)8
Chinese PLA General Hospital6
Assistance Publique - Hôpitaux de Paris4
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University4
Bellicum Pharmaceuticals3
A.O. Ospedale Papa Giovanni XXIII2
AstraZeneca2
Baylor College of Medicine2
Bristol-Myers Squibb2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hematologic Neoplasms143
Leukemia, Myeloid, Acute35
Leukemia25
Myelodysplastic Syndromes25
Lymphoma, Non-Hodgkin22
Multiple Myeloma21
Precursor Cell Lymphoblastic Leukemia-Lymphoma20
Lymphoma18
Leukemia, Lymphocytic, Chronic, B-Cell15
Recurrence15

Trials

Showing 1 to 25 of 143. Each trial links to its page on Pharma Observatory.

43 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.